GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES

Aim. To research on the influence of polymorphism G681A gene CYP2C19 on efficacy of clopidogrel for planned endovascular treatment in stable CHD with second type diabetes.

Material and methods. Totally 242 patients included, with chronic CHD, underwent planned angioplastics and stenting of coronary arteries. Of those 79 had 2nd type DM. All patients received double antiplatelet therapy, including acetylsalicylic acid and clopidogrel. For efficacy evaluation, we performed the test of induced platelet aggregation with ADP in 2,5 and 5,0 mcM concentrations after total dose of clopidogrel 300 mg. Genotyping was done with allele-specific polymerase chain reaction with commercial panel “SNP-express” (SPC “LITECH”, Moscow).

Results. In our selection, the carriers of allele A differed from homozygous GG with an increased grade of platelet aggregation in ADP stimulation, concentrations 2,5 mcM and 5,0 mcM. While selecting subgroups according to diabetes existence, the mention association was found in non-diabetic group, but not in comorbidity group (CHD and DM). In GG genotype, patients having 2 type DM showed the grade of induced platelet aggregation higher than in carriers of the same genotype without DM. At the same time, allele A carriers without DM did not differ from comorbidity selection in sense of ADP induced response of platelets.

Conclusion. So, A allele carriage of G681A polymorphism of gene CYP2C19 is a risk factor for lower clopidogrel efficacy. Diabetes of second type also negatively influences the sensitivity to clopidogrel, but only in GG homozygous. 

1. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.

2. Gratsiansky NA. Antiplatelet therapy for coronary heart disease. Some of the challenges and achievements. Atherotrombosis 2010; 1: 2-54. Russian (Грацианский Н. А. Анти тромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения. Атеротромбоз 2010, 1: 2-54).

3. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel nonresponse in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010; 8(5): 923-33.

4. Rebrova TY, Muslimova EF, Afanayev SA, et al. Resistance to clopidogrel and P2RY12 genes polymorphisms and JPII in patients with coronary heart disease. Clin Medic 2013; 8: 29-31. Russian (Реброва Т. Ю., Муслимова Э.Ф., Афанасьев С. А. и др. Резистентность к клопидогрелу и полиморфизмы генов P2RY12 и GPIIIA у больных ишемической болезнью сердца. Клиническая медицина 2013, 8: 29-31).

5. Ganukov VI, Protopopov AV. Medical escorts of percutaneous coronary intervention. Novosibirsk: Areal; 2014. Russian (Ганюков В.И., Протопопов А.В. Медикаментозное сопровождение чрескожного коронарного вмешательства. Новосибирск: Ареал; 2014).

6. Chernyak YuI, Kolesnikov SI, Chernyak EV. Cytochrome P450: basic understanding, research methods, the value for practical medicine: Stud. method. Irkutsk: Izdatelstvo of University; 2014. Russian (Черняк Ю. И., Колесников С. И., Черняк Е. В. Цитохром P450: основные представления, методы исследования, значение для практической медицины: учеб. метод. пособие. Иркутск: Изд-во ИГУ; 2014).

7. Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. Brit J of Diabetes and Vascular Disease 2013; 15(7): 192-207.

8. 2013 ESC Guidelines on the management of stable coronary disease. Russ J Cardiol 2014; 7(111): 7-79. Russian (Рекомендации по лечению стабильной ишемической болезни сердца. ESC, 2013. Российский кардиологический журнал 2014; 7 (111): 7-79).

9. Buryakina TA, Zateyshchikov DA. The use of reversible inhibitors of P2U12 receptor in acute coronary syndrome. Kardiologiia 2012; 52 (4):74-9. Russian (Бурякина Т. А., Затейщиков Д. А. Место обратимых ингибиторов рецепторов Р2У12 при остром коронарном синдроме. Кардиология 2012; 52(4): 74-9).

10. Wiviott SD, Braunwald E, McCabe CH, et al. for the TRITON–TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007; 357 (15): 2001-15.

11. Nishio R, Shinke T, Otake H, et al. Effect of Cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circulation 2012; 76: 2348-55.

12. Gruzdeva OV, Kremeno SV, Suslova TE, et al. Hemostasis and glucose metabolism in patients with a combination of diabetes mellitus type 2 and hypertension. Siberian Medical Journal (Tomsk) 2008; 23(4): 28-30. Russian (Груздева О. В., Кремено С. В., Суслова Т. Е. и др. Тромбоцитарный гемостаз и показатели углеводного метаболизма у больных с сочетанием сахарного диабета 2-го типа и артериальной гипертензии. Сибир. мед. Журн. (Томск) 2008; 23 (4): 28-30).

13. Vershinina EO, Repin AN, Ryabova TR, el al. The impact of multifocal atherosclerosis on the early and late outcomes of planned endovascular treatment of ischemic heart disease. Siberian Medical Journal (Tomsk) 2013; 28(4): 23-32. Russian (Вершинина Е. О., Репин А. Н., Рябова Т. Р. и др. Ближайшие и отдаленные результаты плановых эндоваскулярных вмешательств на коронарных артериях в зависимости от нарушений углеводного обмена. Сибир. мед. Журн. (Томск). 2013; 28 (4): 25-32).

14. Makeeva O. A., Zykov M. V., Golubenko M. V. et al. Role of genetic factors in predicting complications throughout the year after myocardial infarction. Kardiologiia 2013; 53(10): 16-23. Russian (Макеева О. А., Зыков М. В., Голубенко М. В. и др. Роль генетических факторов в прогнозировании осложнений на протяжении года после инфаркта миокарда. Кардиология 2013; 53(10): 16-23).